Go to the Content   Tuesday, 9 February 2010
 
Home > Policies > Health & society

Articles in this set

Health & society

Health Quarterly: Patients' rights

Picture 1

Healthcare in the European Union is riddled with political and economic challenges, but the law is shifting to give individual patients the treatment they are entitled to.

 

This European Voice special report is made available online for all visitors thanks to Eli Lilly & Company.

Eli Lilly & Company

 


EU hopefuls get ready for their health-check

By Toby Vogel
12.02.2009 / 00:00 CET
Inequality and under-investment are still problems for many countries in the south-east of Europe.

Thirteen years after the end of the war in Bosnia and Herzegovina, returning ref-ugees often find themselves barred from local health facilities because they have dropped out of the state-run health insurance. 

Bosnia's two autonomous regions have their own insurance systems (in one region this is further fragmented into ten cantonal funds) and contributors tend to have difficulty switching from one to another – for example, when they return to their pre-war homes in a different region.

quote
Access is a key issue for patients in many European Union hopefuls in the south-east of Europe, and it is especially acute for vulnerable groups such as refugees
quote

A number of international assistance projects over the years have helped improve specific aspects of policy-making and service delivery, but basic problems of under-investment and inequity remain.

Vulnerable groups

Bosnia is an extreme case – but access is a key issue for patients in many European Union hopefuls in the south-east of Europe, and it is especially acute for vulnerable groups such as refugees or Roma.

These countries – Albania, Turkey and most of the Yugoslav successor states – are lagging far behind the European average in economic and social development, although Croatia tends to do better on most counts.

In the latest human development ranking compiled by the United Nations Development Programme, Bosnia ranks last in the group of countries with high development, and Turkey tops the category of countries with medium human development.

In 2006, Turks had a life expectancy at birth of 71.6 years, which is close to Bulgaria's (72.9) but far behind that of most other EU member states.

Turkey also has the highest child mortality of any member of the Organisation for Economic Co-operation and Development.

But health outcomes are not only a reflection of social and economic conditions.

“The health status of Turkish citizens is poor compared with countries of similar economic and development situation,” a study commissioned by the European Parliament in 2006 found.

This is in part the result of systemic problems found across south-east Europe, especially in governance of the health sector.

Streamlined

Governments in the region are now trying to cut back the dominant role of the state in the provision of health services, focusing instead on policy, funding and standards, in the hope that this will lead to more streamlined and effective systems.

But policymaking at present is fragmented and implementation poor, which produces overbearing yet ineffective state intervention.

At the same time, where reforms are undertaken – with Turkey and Serbia at the forefront – major investments in physical infrastructure and education and training are also needed.

Twin challenges

As these countries emerge from decades of mismanagement and under-investment – compounded in the Balkans by the direct and indirect effects of war – they grapple with twin challenges: infectious diseases typical of transition countries (tuberculosis is still widespread, as are smoking and reckless driving), and at the same time, a growing incidence of diseases typical of middle-income countries, with conditions such as obesity presenting a serious threat to public health.

Awareness both among the public and policymakers is growing, however.

Dr Nata Menabde, deputy regional director for the World Health Organization/Europe in Copenhagen, said the Turkish government has undertaken “bold moves” in dealing with smoking as a public-health issue, despite pressure from the country's big tobacco industry.

More generally, Menabde sees the political will in most countries to deliver better results with limited funds, and a “substantial reform” in primary healthcare is under way.

Turkey, she said, now invests “substantial amounts” in its health sector. According to Menabde, this is not so much a reflection of inefficiencies as of the government's priorities.

“Turkey has put a lot of resources into making services available to the poor,” she said.

Such reforms have mostly been driven by political agendas, even by individual politicians, who recognise the electoral value of providing quality services to taxpayers.

Accession

But the process of EU accession has also boosted the reformers. Even though health is not a focus of the accession process – in the EU, the organisation of the health sector is a national prerogative, and the acquis communautaire does not prescribe a specific model – the cumulative requirements of good governance, transparency, prudent spending and non-discrimination provide powerful pressure in the direction of reform.

© 2010 European Voice. All rights reserved.
Picture 1
Taking the pulse of europe Many countries that are hoping to join the EU are lagging far behind the European average in terms of healthcare. ISTOCK
Picture 1
Related articles

Advertisement

Comments

 

Your comment
Please note: The fields followed by an asterisk (*) are obligatory fields

Comment*

Name*
E-mail*
Website
 I accept the Terms & conditions
 I would like to share my e-mail & website

Eli Lilly & Company

Eli Lilly & Company is a leading innovation-driven pharmaceutical company. Lilly is actively engaged in efforts to combat counterfeit medicines in order to protect the health and safety of patients, including: seeking to secure the integrity of Lilly products throughout the supply chain; deterring criminal activity; and partnering with government and other stakeholders to strengthen enforcement and raise awareness.

In just two months in 2008 Customs across the EU seized more than 34 million illegal medicines (1).

Lilly welcomes the European Commission's recent proposal (2) to tackle counterfeit pharmaceuticals in the legitimate supply chain, as a useful starting point. We call on the European Parliament and the Council of Ministers to protect patients by legislating on this issue without delay.


1 Brussels, 16 December 2008 IP/08/1980 Customs: Millions of illegal medicines stopped by "MEDI-FAKE" action.
2 Brussels, 10 December 2008 COM(2008) 668: Commission proposal to prevent the entry of falsified [counterfeit] medicinal products into the legal supply chain.